Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioLife Solutions (BLFS – Research Report) and GoodRx Holdings (GDRX – Research Report).
BioLife Solutions (BLFS)
KeyBanc analyst Paul Knight maintained a Buy rating on BioLife Solutions yesterday and set a price target of $30.00. The company’s shares closed last Thursday at $11.39, close to its 52-week low of $8.92.
According to TipRanks.com, Knight is a 3-star analyst with an average return of
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $25.00, implying an 115.0% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
GoodRx Holdings (GDRX)
In a report released yesterday, Scott Schoenhaus from KeyBanc maintained a Hold rating on GoodRx Holdings. The company’s shares closed last Thursday at $4.44, close to its 52-week low of $3.82.
According to TipRanks.com, Schoenhaus is a 1-star analyst with an average return of
GoodRx Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $8.21, representing a 54.0% upside. In a report released today, Goldman Sachs also reiterated a Hold rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BLFS:
- BioLife Solutions Reports Third Quarter 2023 Financial Results
- BLFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insider Trading: BioLife Solutions Stock (NASDAQ:BLFS) Gains on Huge Insider Buy
- BioLife Solutions price target lowered to $20 from $25 at TD Cowen
- BioLife Solutions reports Q3 preliminary revenue $33.3 M, consensus $32.72M
